SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001558370-24-010208
Filing Date
2024-07-25
Accepted
2024-07-25 17:26:45
Documents
17
Period of Report
2024-07-25
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K fbio-20240725x8k.htm   iXBRL 8-K 49378
2 EX-99.1 fbio-20240725xex99d1.htm EX-99.1 14470
3 GRAPHIC fbio-20240725xex99d1001.jpg GRAPHIC 12243
  Complete submission text file 0001558370-24-010208.txt   274374

Data Files

Seq Description Document Type Size
4 EX-101.SCH fbio-20240725.xsd EX-101.SCH 4832
5 EX-101.DEF fbio-20240725_def.xml EX-101.DEF 14890
6 EX-101.LAB fbio-20240725_lab.xml EX-101.LAB 13024
7 EX-101.PRE fbio-20240725_pre.xml EX-101.PRE 15197
19 EXTRACTED XBRL INSTANCE DOCUMENT fbio-20240725x8k_htm.xml XML 7218
Mailing Address 1111 KANE CONCOURSE SUITE 301 BAY HARBOR ISLANDS FL 33154
Business Address 1111 KANE CONCOURSE SUITE 301 BAY HARBOR ISLANDS FL 33154 781-652-4500
Fortress Biotech, Inc. (Filer) CIK: 0001429260 (see all company filings)

IRS No.: 205157386 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35366 | Film No.: 241142983
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)